Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$171.51 USD

171.51
6,016,585

+0.92 (0.54%)

Updated Aug 7, 2025 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for HDV

Zacks Equity Research

Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B

by Zacks Equity Research

Pfizer divests its 7.3% remaining stake in Haleon to institutional investors and Haleon itself.

Zacks Equity Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Zacks Equity Research

JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease

by Zacks Equity Research

The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease in adults.

Zacks Equity Research

The Zacks Analyst Blog Highlights Visa, Johnson & Johnson, Thermo Fisher and AMREP

by Zacks Equity Research

Visa, Johnson & Johnson, Thermo Fisher and AMREP are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Visa, Johnson & Johnson & Thermo Fisher Scientific

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Johnson & Johnson (JNJ) and Thermo Fisher Scientific Inc. (TMO), as well as a micro-cap stock AMREP Corporation (AXR).

Zacks Equity Research

Johnson & Johnson (JNJ) Rises But Trails Market: What Investors Should Know

by Zacks Equity Research

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $162.84, denoting a +0.02% change from the preceding trading day.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Johnson & Johnson (JNJ) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Zacks Equity Research

The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J

by Zacks Equity Research

Novo Nordisk, Roche, Pfizer, Arvinas and J&J are part of the Zacks top Analyst Blog.

Zacks Equity Research

Zimmer Biomet Focuses on Innovation Amid Growing Competition

by Zacks Equity Research

Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.

Indrajit Bandyopadhyay headshot

ISRG Stock Price Falls to 200-DMA: Should You Buy, Hold or Sell?

by Indrajit Bandyopadhyay

Intuitive Surgical has maintained an uptrend since late 2022 with price correcting to 200-DMA a few times and again continuing the uptrend. Will it repeat?

Kinjel Shah headshot

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

by Kinjel Shah

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

Zacks Equity Research

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Equity Research

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

by Zacks Equity Research

The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.

Derek Lewis headshot

Are High-Yield Dividend Stocks Best for Income-Focused Investors?

by Derek Lewis

Dividends come with many clear benefits, including a passive income stream and a shield against drawdowns in other positions.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Coca-Cola, Philip Morris and Johnson & Johnson

by Zacks Equity Research

Coca-Cola, Philip Morris and Johnson & Johnson are part of the Zacks Investment Ideas article.

Zacks Equity Research

Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson

by Zacks Equity Research

Gilead Sciences and Johnson & Johnson are part of the Zacks Investment Ideas article.

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Shaun Pruitt headshot

Buy Gilead Sciences (GILD) Stock at 52-Week Highs?

by Shaun Pruitt

Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks.

Zacks Equity Research

JNJ Halts Development of Depression Drug Over Efficacy Concerns

by Zacks Equity Research

While J&J is yet to give up on aticaprant, it decides to stop developing the drug for major depressive disorder due to a lack of sufficient efficacy.

Derek Lewis headshot

3 Dividend Kings Shaking Off Market Woes

by Derek Lewis

While the market throws its tariff tantrum, several long-established companies with years of operational success have seen their shares move higher, displaying relative strength.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Kinjel Shah headshot

Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More

by Kinjel Shah

Bayer announces fourth-quarter results. NVO cuts cost of Wegovy for the uninsured. ABBV enters obesity space with new deal.

Zacks Equity Research

Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DGRO